Spectinomycin Antibiotics (mSPCs) (SJ-13-0041)

St. Jude Reference #SJ-13-0041


Researchers have developed aryl substituted aminomethyl spectinomycin (eAmSPCs) antibiotics as potential broad-spectrum antibiotics which could be developed into therapeutics to treat many infections, including those resistant to current treatments, and biodefense pathogens; while exhibiting improved safety and pharmacokinetic properties.

Recent advances include a new drug structure which can address antibiotic resistance to Mycobacterium abscessus (Mab); a species of rapidly growing, multi-drug resistant mycobacteria, distantly related to the bacterium that causes tuberculosis, which is known to contaminate medications and products such as medical devices. Researchers at St. Jude developed a structure which is up to 64-fold more potent against Mab than regular spectinomycin, and identified the mechanism of action of these eAmSPCs.


Aryl substituted aminomethyl spectinomycin (mSPCs) antibiotics, multi drug resistant infections, biodefense pathogens, improved safety, improved pharmacokinetics, Mycobacterium abscessus (Mab), mycobacteria, tuberculosis, spectinomycin.

Granted patents or published applications

US Patent 10,266,544; Japan 6,545,177; Canada 2,924,733; Australia 2014324535; Europe 9,528,976.

Related scientific references

Lee et al., “Development of 2nd generation aminomethyl spectinomycins that overcome native efflux in Mycobacterium abscessus,” Proceedings of the National Academy of Sciences, Jan. 5, 2024.

Licensing opportunities

We are currently seeking licensees for the development of this antibiotic technology. 

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.